Dechra Veterinary Products is to launch a new lower dose tablet to enhance its existing Felimazole range for the treatment of hyperthyroidism in cats.
Felimazole is licensed for veterinary use for the treatment of feline hyperthyroidism and is currently available in 2.5 mg and 5 mg tablets, but Dechra will launch a 1.25mg tablet in January 2014.
The 1.25mg tablet has been developed following requests from veterinary specialists to enable greater precision and flexibility for veterinary professionals when prescribing the product.
Dechra Veterinary Products brand manager Craig Sankey said: “The extension of the range with a new 1.25mg tablet will assist vets in managing this common endocrine disorder.
“Leading endocrinology experts recommend that the dose of anti-thyroid medication is titrated to obtain circulatory total thyroxine concentrations in the lower half of the reference interval. Hyperthyroidism requires careful understanding and management by both vets and owners, and this new product allows increased precision and flexibility in the treatment process when titrating optimal Felimazole doses.”
Veterinary professionals registered with the Dechra Academy can access free of charge CPD sessions online on how to take control of hyperthyroidism, while a range of new client support materials are also available free of charge to veterinary practices.
For further information on Felimazole tablets, visit www.dechra.co.uk